Home
Live Updates
FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition : comparemela.com
FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition
/PRNewswire/ -- Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved RivflozaTM (nedosiran) injection 80 mg, 128 mg, or...
Related Keywords
Plainsboro ,
New Jersey ,
United States ,
American ,
Novo Nordisk ,
David Heiberg Landsted ,
Nicole Ferreira ,
Blandine Lacroix ,
Prnewswire Novo ,
Rare Disease At Novo Nordisk Inc ,
Facebook ,
Twitter ,
Drug Administration ,
Instagram ,
American Kidney Fund ,
Kidney International ,
Dicerna Pharmaceuticals Inc ,
Novo Nordisk Health Care ,
Journal Of The American Society Nephrology ,
Novo Nordisk Inc ,
Senior Vice President ,
Rare Disease ,
Dicerna Pharmaceuticals ,
Genotype Correlations ,
Estimated Carrier Frequencies ,
American Society ,
Kidney Fund ,
Adults With Primary Hyperoxaluria Type ,
Primary Hyperoxaluria Type ,
Term Extension Study ,
Primary Hyperoxaluria ,
Nordisk All ,
comparemela.com © 2020. All Rights Reserved.